Follow The Filings

LPCN Lipocine

Lipocine earnings company data as of 7:50 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by LPCN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LPCN insider trades
  • $517K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. John W. Higuchi Director
    Buy
    $55K 25,007 shares at $2.20 +12% to stake
    Traded Sep 29–30 Filed Oct 1
  2. John W. Higuchi Director
    Buy
    $27K 12,561 shares at $2.16 +6.2% to stake
    Traded Sep 28 Filed Sep 30
  3. John W. Higuchi Director
    Buy
    $81K 40,000 shares at $2.03 +24% to stake
    Traded Apr 7 Filed Apr 7
  4. John W. Higuchi Director
    Buy
    $252K 123,000 shares at $2.05 +302% to stake
    Traded Apr 6 Filed Apr 6
  5. Mahesh V. Patel CEO
    Buy
    $51K 25,000 shares at $2.03 +18% to stake
    Traded Apr 6 Filed Apr 6
  6. Mahesh V. Patel CEO
    Buy
    $51K 25,000 shares at $2.02 +23% to stake
    Traded Apr 2 Filed Apr 2

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01
8-K 8.01,9.01
8-K/A 5.02
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 5.02,7.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 5.02,5.07,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 8.01,9.01
DEF 14A
8-K 5.02
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.